Lung cancer[1] , or cancer that starts in the lungs, is the leading cause of cancer death in the United States, with smokers at greatest risk for contracting the disease. According to the National Institutes of Health[2] , lung cancer is more common in older adults and rarer in people ...
Molinier L, Combescure C, Chouid C, et al. Cost of lung cancer. A methodological review. Pharmacoeconomics. 2006;24:651-659.Molinier L, Combescure C, Chouaid C, Daures JP, Housset B, Fabre D, Grand A, Vergnenegre A : Cost of lung cancer: a methodological review. Pharmacoeconomics ...
Most of the researches in China about direct medical cost of lung cancer are comparative studies between difference chemotherapies, which is not the focus paper of this review. The only target paper studied in-hospital cost per capita per time. The reason could be lacking data and methodology ...
Racial‐ethnic disparity • Lung cancer • End‐of‐life care • Cost and utilizationThe end‐of‐life period is a crucial time in lung cancer care. To have a better understanding of the racial‐ethnic disparities in health care expenditures, access, and quality, we evaluated these ...
In lung cancer, there is a significant incidence of bone metastases with skeletal complications affecting more than 50% of patients. The systematic detection of bone metastases should be included in the initial staging of lung cancer in order to begin their management at an early stage. Treatment...
BACKGROUNDLung cancer is the leading cause of cancer death in the U.S., with an estimated annual economic burden of $5 billion. Clinical trials offer innovative therapeutic options with potentially better outcomes, but their effects on health care costs are disputed.METHODSThe authors analyzed the...
Aim: To evaluate the cost utility and budget impact of second-line gefitinib for non-small cell lung cancer from a Thai payer perspective.Methods: A Markov... S Thongprasert,S Tinmanee,U Permsuwan - Asia-Pacific Journal of Clinical Oncology 被引量: 25发表: 2012年 Quality-of-life and ...
Rosenthal1, P.J. Webster2, V.J. Gebski3, R.C. Stuart-Harris4, A.O. Langlands1, J. Boyages1. Depts of Radiation Oncology1, Pharmacy2, Medical Oncology4, Westmead Hospital and Dept of Biostatistics3, Macquarie University, N.S.W.doi:10.1016/0169-5002(91)91891-ENoneLung Cancer...
The aim of our study was to evaluate the cost of the tumor marker assays most widely used in pneumological practice and the effectiveness of the percentage of DRG-based reimbursements absorbed by these assays. For this purpose we assessed the cost of lung tumor marker assays in Emilia Romagna...
We examined the impact of different predictive biomarker screening techniques and population enrichment criteria on the cost-effectiveness of targeted drugs in lung cancer, using ALK and crizotinib to build the initial model.Health economic modeling of cost per Quality Adjusted Life Year was based on ...